Navigation Links
Horizon Pharma Announces Issuance of U.S. Patent Covering RAYOS (delayed-release prednisone)
Date:5/29/2012

DEERFIELD, Ill., May 29, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ:  HZNP) announced today that the U.S. Patent and Trademark Office has issued patent number 8,168,218 titled "Delayed Release Tablet with Defined Core Geometry" that covers RAYOS® (5 mg Delayed-Release Prednisone).  Horizon is the licensee of the SkyePharma group of companies in respect of the patent and SkyePharma's related proprietary Geoclock™ technology.

"This patent issuance for RAYOS is another important milestone as we continue to solidify intellectual property protection for our entire product portfolio," said Timothy P. Walbert, chairman, president and chief executive officer of Horizon.

About RAYOS
RAYOS, known as LODOTRA® in Europe, is a proprietary delayed-release formulation of low-dose prednisone. The proprietary formulation technology of RAYOS enables a delayed-release of prednisone approximately four hours after administration. RAYOS synchronizes the prednisone delivery time with the patient's elevated cytokine levels, thereby taking effect at a physiologically optimal point to inhibit cytokine production. RAYOS utilizes SkyePharma's proprietary Geoclock™ technology.

Outside the United States, LODOTRA is approved for the treatment of moderate to severe active rheumatoid arthritis (RA) when accompanied by morning stiffness in 16 European countries and Israel and is marketed in Europe through Horizon's distribution partner Mundipharma International Corporation Limited, who also has commercial rights in certain Asian and Latin American countries. Approval in Europe was based on the CAPRA-1 study, which was a 12-week, double-blind, placebo controlled study evaluating 288 RA patients. CAPRA-1 compared the night-time administration of LODOTRA with the morning administration of immediate release prednisone at the same individual dose (average prednisone dose was 6.7 mg). Results from CAPRA-1 demonstrating a statistically significant reduction in the duration of morning stiffness associated with RA compared to patients in the immediate release group, the primary outcome of the trial (22.7 percent for LODOTRA compared to 0.4 percent for immediate release prednisone [p-value = 0.045]), were published in The Lancet 2008 (371: 205-214).

Horizon has completed the Phase 3 CAPRA-2 study for RAYOS in the United States, Europe and Canada for the treatment of the signs and symptoms of RA and in November 2011, the U.S. Food and Drug Administration accepted for filing and review Horizon's New Drug Application for RAYOS. The PDUFA action date is July 26, 2012 based on a standard 10 month review.

About Horizon Pharma

Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. For more information, please visit www.horizonpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding Horizon and its business prospects.  These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release, and Horizon undertakes no obligation to update or revise these statements, except as may be required by law.

Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
investor-relations@horizonpharma.com

Media
Geoff Curtis
DJE Science
312-233-1253
geoff.curtis@djescience.com

Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
kgalante@burnsmc.com


'/>"/>
SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ECRI Institute Awarded AHRQ Contract to Establish National Healthcare Horizon Scanning System
2. HORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS® Drug-Eluting Stent in Heart Attack Patients
3. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
4. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
5. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
6. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
7. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
8. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
9. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
10. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
11. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
(Date:4/28/2016)... Treato , the single ... today that it has been named a Cool Vendor ... Life Sciences, 2016, Stephen Davies , ... on life-science- oriented analytics, algorithms and smart machine technology ... confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life sciences, ... team to bring a wealth of insight to a growing business. ... knowledge. George Phillips joined ArisGlobal in the ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... ... This week Omega Institute, a premier nonprofit educational retreat center in New ... is offering a record 370 in-person workshops and new online learning opportunities and ... in or need for the knowledge and skills we’ve been cultivating for nearly 40 ...
(Date:5/2/2016)... Orange County, CA (PRWEB) , ... May 02, 2016 , ... ... study now linking dental health and cognitive decline. According to the research, which was ... seniors have some degree of cognitive decline, and about 5.4 million Americans have Alzheimer’s ...
(Date:5/2/2016)... PORT RICHEY, Fla. (PRWEB) , ... ... ... experts and medical researchers report that many commonly used prescription medications, including ... loss (1). To mitigate these risks, Novus Medical Detox Center —a ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Sixth ... held at the Bellagio Hotel in Las Vegas, NV from October 17–19, 2016. ... be co-hosting the event. , This year’s conference will offer presentations featuring ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... EVP and GM Jim Callandrillo and Duane Reed, VP of business development ... Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting from May 15-17 ...
Breaking Medicine News(10 mins):